Paxlovid plus glucocorticoids treatment in severe Omicron infected patients with hypoxaemia: A prospective multiple-center cohort study
Our study demonstrated the benefit of Paxlovid plus glucocorticoid administration in hospitalized Omicron infection patients with hypoxaemia. These results, as least partly, supported direct evidence about the necessity of antiviral treatment in severe COVID-19 patients with hypoxaemia.
Authors
- Yuji Wang (ORCID: https://orcid.org/0000-0003-3842-7627)
- Ran Wang (ORCID: https://orcid.org/0000-0002-8199-6895)
- Nan Su (ORCID: https://orcid.org/0000-0002-4564-1595)
- Jiao Zhu (ORCID: https://orcid.org/0000-0002-8152-5268)
- Guifang Xu (ORCID: https://orcid.org/0000-0001-9949-3658)
- Daxiong Zeng (ORCID: https://orcid.org/0000-0002-6476-2974)
- Junhong Jiang
Institutions
- Anhui Medical University (CN)
- Soochow University (CN)
- Suzhou Municipal Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- First Affiliated Hospital of Soochow University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1371/journal.pone.0328929
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00